|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
NEOPLASIA
From the Department of Haematological Medicine, Guy's,
King's, Thomas' School of Medicine, London, United Kingdom.
Bone marrow CD34+ cell apoptosis (annexin V),
proliferation (Ki-67), and Bcl-2-related protein expression was
evaluated by flow cytometry in 102 patients with myelodysplastic
syndrome (MDS) and acute myeloid leukemia secondary to MDS (MDS-AML)
and in 30 normal donors (NBM). Apoptosis was significantly increased in refractory anemia (RA)/RA with ringed sideroblasts (RARS) (56.9% [20.4%-93.6%]) and refractory anemia with excess blasts (RAEB) (51.2% [25.2%-76.6%]) compared with NBM (16.7% [3.4%-35.3%],
P < .0001). In RA/RARS, apoptosis always exceeded
proliferation (Ki-67-positivity, 26.1% [9.5%-47.8%];
apoptosis:proliferation ratio 2.08 [1.15-3.63]); whereas in RAEB,
this ratio equalized (1.14 [0.93-2.08]) due to increased
proliferation (40.4% [22%-69.5%]). Progression to RAEB in
transformation (RAEB-t)/MDS-AML was associated with a significant
reduction in apoptosis (22.3% [2.1%-53.2%]; P < .0001) and proliferation (16.8% [1.9%-75.8%);
P = .04; ratio 1.69 [0.16-12.21]). Pro-apoptotic
(Bax/Bad) versus anti-apoptotic (Bcl-2/Bcl-X) Bcl-2-related protein
ratios were increased in RA/RARS compared with NBM (2.57 [1.93-9.42]
versus 1.89 [0.65-4.1]; P = .06), whereas disease
progression was associated with significantly reduced ratios (1.16 [0.06-3.32]; P < .0001) due primarily to increased
Bcl-2 expression. Apoptosis and Bax/Bad:Bcl-2/Bcl-X ratio were
inversely correlated with both International Prognostic Scoring System
score and cytogenetic risk group; highest levels observed in patients
with low score and/or good risk cytogenetics. There was a trend toward
an association between Bcl-2-related protein expression and apoptosis
(P = .07). This study indicates that MDS progression
arises through multiple hits that alter levels of CD34+
cell apoptosis and proliferation. Early disease is associated with
excessive apoptosis and elevated ratio of apoptosis to proliferation. Increased proliferative rates are observed in RAEB, whereas leukemic transformation arises through inhibition of apoptosis rather than excessive cell growth. Although disease progression is accompanied by a
fall in pro-apoptotic versus anti-apoptotic Bcl-2-related protein
ratios, heterogeneity in patterns of protein expression indicates that
factors additional to Bcl-2 family members play a role in the
deregulated apoptosis in MDS.
(Blood. 2000;96:3932-3938) The myelodysplastic syndromes are clonal stem cell
disorders characterized by dysplastic hematopoiesis and an increased
risk of leukemic transformation, especially in advanced subtypes:
refractory anemia with excess blasts (RAEB) and RAEB in transformation
(RAEB-t).1 Despite a normal or hypercellular marrow, most
patients present with peripheral blood cytopenias. This paradox has
recently been attributed to excessive programmed cell death or
apoptosis of hematopoietic progenitors.2,3 Apoptosis in
early disease may represent a pathophysiological mechanism whereby the
hematopoietic system is able to abrogate defective and/or potentially
harmful clones. Alternatively, an early "hit" in the multistep
pathogenesis of myelodysplastic syndrome (MDS) could give rise to a
clone with a proliferative advantage. Increased apoptosis may thus
represent a homeostatic process to control cell numbers. In turn,
leukemic progression could arise through the acquisition of genetic
lesions that either block programmed cell death (PCD) or promote
proliferation over and above apoptosis.
PCD can be triggered by a variety of extracellular stimuli and
intracellular signals. Major regulators of these apoptotic pathways are
members of the Bcl-2 family. These proteins function as homodimers or
heterodimers, and it is the ratio of pro-apoptotic versus
anti-apoptotic molecules that determines a cell's susceptibility to
death signals.4 Deregulation of Bcl-2 family members has been demonstrated in a variety of human cancers, including
hematological malignancies,5,6 and could feasibly underlie
aberrant PCD observed in MDS. Certainly, increased expression of the
anti-apoptotic protein Bcl-2 compared to pro-apoptotic Bax has been
associated with disease progression in chronic lymphocytic
leukemia.7 Moreover, in acute myeloid leukemia (AML),
Bcl-2 overexpression is linked with CD34 positivity, resistance to
chemotherapy, and short survival,6,8 features commonly
attributed to disease arising from MDS. Studies demonstrating reduced
Bcl-2 expression in CD34+ cells of patients with early MDS
subtypes compared to advanced disease and normal controls lends further
support for a role of the Bcl-2-related proteins in the pathogenesis
of deregulated apoptosis and ineffective hematopoiesis in
MDS.9,10 In the present study, the relationship between
hematopoietic progenitor cell apoptosis and proliferation at different
stages of MDS evolution was investigated by 2-color flow cytometry,
using anti-CD34 monoclonal antibody (Mab) to identify progenitor cells,
annexin V that binds to exposed phosphatidylserine on apoptotic
cells11 and Ki-67 Mab that specifically binds to DNA of
cycling cells.12 Permeabilized anti-CD34-labeled cells
were also incubated with conjugated antibodies to 2 pro-apoptotic (Bax
and Bad) and 2 anti-apoptotic (Bcl-2 and Bcl-X) Bcl-2 family members to
evaluate whether deregulated apoptosis could be attributed to altered
expression of the Bcl-2-related proteins.
Patient characteristics
The degree of apoptosis, proliferation, and Bcl-2-related protein
expression was evaluated in 117, 56, and 44 cases, respectively. Data
regarding Bcl-2-related protein expression has been previously published.13 According to the French, American, British
(FAB) morphologic guidelines for MDS classification,14 48 patients had refractory anemia (RA), 4 had RA with ringed sideroblasts (RARS), 15 had RAEB, 7 had RAEB-t, and 28 had MDS-AML. Within this
subset of patients, 6 had AML that had progressed from chronic myelomonocytic leukemia (CMML), and 5 had relapsed following
chemotherapy. No patient had received any therapy other than supportive
care for at least 1 month prior to BM examination. Median age was 67 years (range 17-92) with no significant differences between diagnostic categories. Hemoglobin (P = .002) as well as white cell
(P = .004) and platelet counts (P = .0002),
however, differed significantly between the disease subgroups. Of the
50 evaluable patients with early MDS, 38 (76%) had "good risk"
cytogenetics according to the International Prognostic Scoring System
(IPSS; normal karyotype or isolated deletions of the long arm of
chromosome 5 or 20 or -Y).15 In contrast, 17 of 32 (53%)
patients with RAEB-t/MDS-AML harbored a "poor risk" karyotype (> 2 chromosomal abnormalities and/or abnormalities of chromosome 7) with 14 (44%) demonstrating abnormalities of chromosome 7 (Table
1).
Apoptosis quantification BM mononuclear cells were isolated by density gradient centrifugation over Ficoll-Paque (d = 1.077 g/mL; Pharmacia Biotech) and washed twice in phosphate-buffered saline (PBS) (Sigma). A total of 106 cells were used per sample. Cells were incubated with phycoerythrin (PE)-conjugated anti-CD34 Mab (Clone 8G12, Anti-HPCA-2, IgG1; Becton Dickinson) for 20 minutes at room temperature in the dark and then washed twice in PBS. Pelleted cells were resuspended in 100 µL binding buffer (10 mmol/L Hepes/NaOH, pH 7.4, 140 mmol/L NaCl, 2.5 mmol/L CaCl2; Bender Medsystems, Boehringer Ingelheim) and incubated with 2 µL fluorescein isothiocyanate (FITC)-conjugated annexin V (Bender Medsystems, Boehringer Ingelheim) for 10 minutes at room temperature in the dark. Cells were then resuspended in 400 µL binding buffer prior to flow cytometric analysis. Negative controls included MNCs incubated with neither CD34-PE Mab nor annexin V-FITC and cells incubated with CD34-PE Mab only.Ki-67 expression For cell surface and intracellular protein staining, fresh whole BM containing 106 white blood cells per sample was used. Cells were incubated with PE-conjugated anti-CD34 Mab (Clone 8G12, Anti-HPCA-2, IgG1; Becton Dickinson) for 20 minutes at room temperature in the dark and then washed twice in PBS. Samples were fixed in 100 µL "medium A" that contained formaldehyde (Fix & Perm, Caltag Laboratories, TCS Biologicals) for 15 minutes at room temperature in the dark and then washed in PBS to which 2.5% fetal calf serum (Sigma) and 0.1% sodium azide (Sigma) had been added (PBSF). MNCs were subsequently incubated with 100 µL permeabilization "medium B" (Fix & Perm, Caltag Laboratories, TCS Biologicals) and FITC-conjugated Ki-67 Mab (Clone MIB-1, IgG1; Immunotech, Coulter) for 20 minutes at 4°C in the dark and then washed in ice-cold PBSF. Cell pellets were resuspended in ice-cold PBSF prior to flow cytometric analysis. Cells incubated with FITC-conjugated isotype-specific antibodies (Serotec) were used as negative controls.Bcl-2-related protein analysis BM cells (106) were incubated with FITC-conjugated anti-CD34 Mab (Becton Dickinson) for 20 minutes at room temperature in the dark and then washed twice in PBS. Cells were fixed in 100 µL medium A for 15 minutes at room temperature in the dark and then washed in PBS. To prevent nonspecific binding of Mabs to Fc receptors, cells were pre-incubated with 10 µL rabbit-anti-mouse (RAM) immunoglobulins (Dako) for 10 minutes. Permeabilization medium B (100 µL) was subsequently added for a further 10 minutes prior to washing in ice-cold PBSF. To detect intracellular Bcl-2-related protein expression, cells were incubated with Mabs to Bax (Immunotech, Coulter), Bcl-2 (Dako), Bad, and Bcl-X (Transduction Laboratories, Affiniti Research Products) for 30 minutes on ice. After washing in ice-cold PBSF, cells were incubated with PE-conjugated RAM (Dako) for 30 minutes on ice, washed again, and resuspended in ice-cold PBSF prior to flow cytometric analysis. Negative controls were performed by incubating cells with isotype-specific antibodies (Sigma).Flow cytometric analysis Two-color analysis of annexin V, Ki-67 expression, and Bcl-2-related protein levels within CD34+ cell populations was performed, using an EPICS XL flow cytometer (Coulter). Data were acquired in list mode, acquiring at least 2 × 105 events per sample and/or at least 104 events within the CD34+ cell gate. Analysis was based on gating of subpopulations of CD34+ cells by forward scatter versus side scatter as well as side scatter versus fluorescence 2 for apoptosis and Ki-67 detection and fluorescence 1 for Bcl-2-related protein analysis. The percentage of positivity was determined by comparison of the fluorescence distribution histogram of positively stained cells to that of cells to which no annexin V was added for apoptosis, and to cells stained with appropriate isotype control for Ki-67 and Bcl-2-related protein analysis. The mean fluorescence intensity (MFI) value for each Bcl-2-related protein was calculated by dividing the MFI value of the positively stained cells by that of cells stained with an isotype control antibody. To determine individual Bcl-2-related protein levels, we calculated an Oncoprotein Index (OPI) as previously described,9 whereby OPI equals the product of the percentage of positive cells and MFI.Statistical analysis For the purposes of statistical evaluation, patients with RA and RARS were analyzed as one group. Comparison of CD34+ cell annexin V positivity and Ki-67 protein expression as well as apoptosis:proliferation (A:P) and Bax/Bad:Bcl-2/Bcl-X ratios between patients within clinically different disease subgroups was carried out, using the chi-square, Kruskal Wallis, and Mann Whitney tests. Correlations with clinical and laboratory parameters were calculated, using the Spearman rank test. In all statistical calculations, a P value of <.05 was considered significant.
Degree of apoptosis As shown in the representative set of experiments (Figure 1), the degree of CD34+ cell apoptosis was significantly different between the diagnostic subgroups (chi-square 20.9; 2 degrees of freedom [df]; P < .00005). CD34+ cell apoptosis was significantly increased in MDS FAB subtypes RA, RARS (median 56.9% [range 20.4%-93.6%], n = 50), and RAEB (51.2% [25.2%-76.6%], n = 11) compared to normal controls (median 16.7% [range 3.4%-35.3%], n = 26, P < .0001). Of the 50 patients with RA/RARS, 40 (80%) had more than 50% CD34+ cells undergoing PCD. Levels of apoptosis were significantly lower in RAEB-t/MDS-AML (median 22.3% [range 2.1%-53.2%], n = 30) compared to both RA/RARS (P < .0001) and RAEB (P = .0003) but did not differ from normal controls (Table 2). Within this subgroup, patients with AML that had transformed from CMML (n = 5) had the lowest levels of PCD (median 6.2% [range 2.1%-27.8%], P = .03). Differences in CD34+ cell apoptosis between RA/RARS/RAEB and RAEB-t/MDS-AML remained significant even after removal of CMML-AML from this latter category. Comparison of early MDS with RAEB-t alone (P = .0003) and RAEB versus RAEB-t (P = .004) also demonstrated significant differences. When analyzing all patients, the percentage of apoptosis was positively correlated with hemoglobin concentration (Spearman r 0.32, confidence interval [CI] 0.19-0.5, P = .02) and platelet counts (Spearman r 0.45,CI 0.26-0.6, P < .0001), whereas there was an inverse correlation with white cell count (Spearman r 0.26, CI 0.44 to 0.06, P = .01) and IPSS score
(Spearman r 0.36, CI 0.56 to 0.12,
P = .004). Within disease subgroups, however, levels of
PCD were highly variable (Figure 2A) and
could not be correlated with the aforementioned characteristics (data
not shown).
Degree of proliferation Maximal rates of proliferation were observed in patients with RAEB (median 40.35% [range 22%-69.5%], n = 10), which were higher than both normal controls (median 18.7% [range 5.1%-59.6%)], n = 10, P = .05) and RA/RARS (median 26.05% [range 9.5%-47.8%], n = 22, P = .02). Progression to RAEB-t/MDS-AML was associated with a significant reduction in Ki-67 positivity (median 16.85% [range 1.9%-75.8%], n = 14, P = .01) (Table 2). The degree of proliferation within diagnostic subgroups was highly variable, especially in advanced disease, (Figure 2B) and showed no correlation with clinical or laboratory characteristics or IPSS score (data not shown).Apoptosis versus proliferation CD34+ cell proliferation equaled or exceeded apoptosis in 8 of 10 (80%) normal controls (median A:P ratio 0.81 [range 0.48-1.6]), whereas in FAB subtypes RA/RARS, levels of CD34+ cell apoptosis always exceeded S-phase percentage (median A:P ratio 2.08 [range 1.15-3.63], P < .0001), with 13 of 22 (59.1%) patients having an A:P ratio greater than 2. Progression to RAEB was associated with an increase in Ki-67 positivity such that apoptosis mirrored proliferation in 8 of 10 (80%) cases (median A:P ratio 1.14 [range 0.94-2.06], P = .0004). The relationship between apoptosis and CD34+ cell division in RAEB-t/MDS-AML was highly variable (median A:P ratio 1.69 [range 0.16-12.21]); however in 10 of 14 (71.4%) cases, proliferation rates were lower than or matched levels of PCD (Figure 2C). The ratio of apoptosis to proliferation was significantly different between the 3 disease categories (chi-square 7.59, 2 df, P = .023) (Table 2). When considering the group as a whole, there was a significant inverse correlation between A:P ratio and IPSS score (Spearman r =0.39 [CI 0.65 to 0.06)],
P = .02). However, within disease subgroups, A:P
ratio showed no correlation with laboratory parameters.
Disease progression and sequential patient samples Two patients showed evidence of disease evolution during the period of study. In the first case, BM blast percentage increased from 3% to 9% non-erythroid cells, whereas in patient 2, transformation to RAEB-t was accompanied by karyotypic evolution 46, XX to 46, XX, del16 (q22-q24). MDS progression in both cases was associated with a fall in levels of CD34+ cell apoptosis. In the latter patient, in whom proliferation rates were additionally measured, evolution to RAEB-t was accompanied by a concomitant reduction in CD34+ cell proliferation (Figure 3).
Bcl-2-related protein expression As shown in Figure 4, patients with RA/RARS had a higher Bax OPI compared to normal controls (median 92.2 [range 12.2-913], n = 14 versus median 51.4 [range 9.2-170.7], n = 10), whereas progression to RAEB or RAEB-t/MDS-AML was associated with a significant increase in Bcl-2 expression (RA/RARS median OPI, 84.1 [range 9.1-681.7]; RAEB/RAEB-t/MDS-AML median OPI, 336.7 [range 1.1-6448], n = 20, P = .02) and a relative reduction in Bad. A higher pro-apoptotic (Bax/Bad) versus anti-apoptotic (Bcl-2/Bcl-X) apoptotic Bcl-2-related protein ratio was demonstrated in RA/RARS compared to normal controls, although this finding did not reach statistical significance (median 2.57 [range 1.93-9.42] versus median 1.89 [range 0.65-4.1], P = .06). Evolution to RAEB and RAEB-t/MDS-AML, however, was associated with a significant reduction in Bax/Bad versus Bcl-2/Bcl-X ratio (RAEB, median 1.19 [range 1.14-2.08], P = .04; RAEB-t/MDS-AML, median 0.85 [range 0.06-3.32], P = .0002) (Table 2). Of the 14 patients with RA/RARS, 12 (85.7%) had a pro-apoptotic versus anti-apoptotic Bcl-2-related protein ratio greater than 2; conversely, a ratio of 1 was observed in 12 of 20 (60%) patients with more advanced disease. In MDS patients, there was a significant positive correlation between Bax/Bad versus Bcl-2/Bcl-X ratio and platelet count (Spearman r = 0.46, 95% CI 0.11-0.71, P = .01) and a negative correlation with IPSS score (Spearman r = minus 0.67, 95% CI0.87 to 0.26, P = .003). There was a trend toward an association between
Bcl-2-related protein expression and apoptosis, although this finding
failed to reach statistical significance (P = .07). Within
disease subgroups however, patterns of Bcl-2-related protein expression
were highly variable and showed no correlation with the aforementioned
laboratory parameters.
Cytogenetics A significant relationship was observed between PCD and cytogenetic risk group; patients with good risk cytogenetics having the highest degrees of apoptosis (good risk, 55.1% [2.1%-93.6%]; intermediate risk, 46.1% [9.9%-83.8%]; poor risk, 25.8% [3%-86.5%], P = .02). The presence of chromosome 7 abnormalities was particularly associated with reduced CD34+ cell apoptosis (chromosome 7 abnormalities, 23.3% [3%-56.9%] verus other karyotype, 51.4% [9.9%-93.6%], P = .0007) (Figure 5A). Proliferation rates and A:P ratios showed no correlation with karyotype. Cytogenetic risk group also significantly influenced Bcl-2-related protein ratios, with the highest ratios observed in patients with a good risk karyotype (good risk, median 2.36 [range 1.17-9.42]; intermediate risk, median 1.14 [range 0.06-5.77]; poor risk, median 1.17 [range 0.4-2.89], P = .03). Low ratios in patients with intermediate or poor risk cytogenetics was primarily due to increased Bcl-2 expression (Figure 5B). There was also a trend for lower pro-apoptotic versus anti-apoptotic Bcl-2-related protein ratios in patients harboring chromosome 7 abnormalities (chromosome 7 abnormalities, median ratio, 1.16 [range 0.4-2.89] versus other karyotype, median ratio, 2.08 [range 0.05-9.42], P = .08) (Table 3).
Several authors3,9,13,16-21 have demonstrated that excessive intramedullary hematopoietic cell apoptosis may contribute toward the ineffective hematopoiesis characteristic of MDS. Studies demonstrating that early MDS is, in addition, a highly proliferative disorder, with the number of S-phase cells being significantly correlated with the degree of PCD,10,22 have prompted speculation that increased cell division in early disease is a compensatory mechanism to neutralize excessive apoptosis. Alternatively, increased PCD may represent a homeostatic process to counteract high proliferative rates. Data are conflicting, however, regarding the stage of MDS at which apoptosis and/or proliferation is most prominent or indeed, the nature of the primary cell involved.3,9 Moreover, alterations in the balance between cell growth and cell death with disease evolution and the nature of underlying lesions responsible for these changes have not been clearly elucidated. Inconsistencies between studies may be partly explained by the variable cellular composition of MDS BM as well as differences in methodology. Certainly, difficulties in discerning the precise cell type undergoing PCD and/or proliferation, using techniques that identify DNA strand breaks (in situ end labeling [ISEL], terminal dUTP nick-end labeling [TUNEL]) (apoptosis) and DNA incorporation of thymidine analogs (proliferation) in BM biopsy specimens, generally limits analysis to hematopoietic cells as a whole rather than specific cell subtypes.3,10,21 Moreover, TUNEL does not reliably discriminate between apoptosis and cell necrosis.23 In the present study, the degree of PCD and proliferation was evaluated by dual-labeling flow cytometric techniques. Although the precise phenotype of cells undergoing apoptosis in MDS has not yet been clearly defined,3,9 we limited assessment of PCD to CD34+ progenitors to minimize the influence of cellular heterogeneity of different MDS FAB subtypes on outcome. CD34+ cells were also selected for analysis as clonality studies indicate that MDS arises through neoplastic transformation of primitive hematopoietic stem cells.24 Apoptosis determination, using flow cytometric detection of annexin V binding, offers several advantages over older methods. First, the externalization of phosphatidylserine to which annexin V binds can be measured prior to in vitro detection of DNA damage,25 enabling detection of cells in the earliest stages of apoptosis.11,26,27 Moreover, flow cytometric techniques are both rapid, minimizing in vitro induction of cell death, and permit examination of large numbers of cells. In accordance with previous studies, we found that CD34+ cell apoptosis was significantly increased in RA/RARS and RAEB compared to normal controls, whereas leukemic evolution was associated with a marked reduction in PCD.9,17,18,20 We also demonstrated a significant relationship between apoptosis, IPSS score, and cytogenetic risk group; patients with a low score and/or good risk cytogenetics have the highest degrees of annexin V positivity. Conversely, the presence of chromosome 7 abnormalities was associated with significantly reduced CD34+ cell apoptosis. The positive correlation between PCD, hemoglobin concentration, and platelet counts may be secondary to low levels of apoptosis observed in advanced MDS, a disease stage characteristically associated with worsening peripheral cytopenias. Similarly, the inverse correlation with white cell count is probably due to increased numbers of circulating peripheral blasts in RAEB-t/MDS-AML. The degree of apoptosis in the present study is considerably higher than previously reported in a number of published series.9,17,21,28 This probably reflects differences in experimental design. Earlier studies predominantly focused on detection of DNA degradation or morphologic changes, which are late events in the process of apoptosis. Evaluation of BM mononuclear cells rather than stem cells alone may additionally lead to underestimation of the degree of PCD. Authors, who have quantified apoptosis through annexin V staining, have demonstrated similar levels of PCD to the present study. Indeed, Kliche and Andreef28 detected annexin V positivity in 53.4% (mean) BM cells in 28 MDS patients compared to 28% in 12 normal controls.29 In the majority of RA/RARS patients, levels of CD34+
cell apoptosis greatly exceeded proliferation, with 13 of 22 cases
having an A:P ratio greater than 2. This finding indicates that, in
early disease, excessive apoptosis probably represents a
pathophysiological mechanism rather than a compensatory process to
counteract increased cell growth. Cell death might be triggered by the
BM microenvironment, either through a relative deficiency of growth
factors or mediated through stromal immunoregulatory cells in an
attempt to abrogate potentially harmful clones. Certainly, studies
demonstrating elevated tumor necrosis factor In our study, progression to RAEB was associated with an increase in the number of Ki-67-positive cells such that the ratio between apoptosis and proliferation equalized. However, evolution to RAEB-t/MDS-AML was accompanied by a significant reduction in annexin V positivity with an accompanying fall in proliferation in most cases. Previous studies22,35,36 have also demonstrated a fall in the number of s-phase cells with disease progression, with patients with the lowest labeling index being at highest risk of leukemic transformation, indicating that evolution toward acute leukemia, in most cases, arises through genomic lesions that inhibit apoptotic control mechanisms rather than promoting cell growth. Given the primary role of the Bcl-2-related proteins in the control of apoptotic pathways, we sought to determine whether altered expression of Bcl-2 family members was responsible for deregulated CD34+ cell apoptosis in MDS. Increased BM Bcl-2 expression with MDS progression has been previously documented.9,21 However, because many of these studies have measured protein expression in all hematopoietic cells, it could be argued that observed alterations in Bcl-2 levels merely reflect the heterogeneity of cell type in different MDS FAB subgroups. With the use of dual-labeling flow cytometric techniques to restrict analysis to CD34+ progenitors, we found higher Bax/Bad verus Bcl-2/Bcl-X ratios in early MDS compared to normal controls, which appeared to be due to a relative increase in Bax levels. Disease progression was accompanied by a significant fall in pro-apoptotic verus anti-apoptotic Bcl-2-related protein ratio due, in part, to a relative increase in Bcl-2 and a reduction in Bad expression. As with apoptosis, we found a significant negative correlation between Bax/Bad versus Bcl-2/Bcl-X ratios and both IPSS score and cytogenetic risk group. There was also a trend toward an association between Bcl-2-related protein expression and apoptosis, although this finding just failed to reach statistical significance. Patterns of Bcl-2-related protein expression, however, varied widely, even within disease subgroups, indicating that mechanisms additional to Bcl-2-related protein expression are involved in the regulation of apoptosis in MDS. Our study indicates that MDS progression arises through multiple genomic hits that alter both the balance between apoptosis and proliferation and the ratio of pro-apoptotic versus anti-apoptotic Bcl-2-related proteins. As well as providing a model for the multistep pathogenesis of cancer in general, a clearer understanding of the molecular events leading to deregulation of the balance between cell growth and cell death in MDS should permit the identification of therapeutic targets, diagnostic markers, and useful indicators of prognosis.
We are indebted to Keith L. Fishlock for his assistance in flow cytometric analysis; Barbara Czepulkowski for cytogenetic analysis; Dr F. Al Refaie, Princess Alexandra Hospital, Harlow; Dr R. Carr, St Thomas' Hospital, London; Dr J. Duncan, Royal Sussex County Hospital, Brighton; Drs C. G. Taylor and D. S. G. Gillett, Pembury Hospital; Dr J. P. L. A. Hayes, All Saint's Hospital, Chatham; Drs R. M. Ireland and P. Black, Greenwich Hospital; Drs R. Jan-Mohamed and R. Kaczmarski, The Hillingdon Hospital; Dr Mir, Lewisham Hospital; Drs S. M. B. Rassam and S. Ward, Queen Mary's Hospital, Sidcup; Dr V. Ratnayake, The William Harvey Hospital, Ashord; Dr I. R. Samaratunga, Farnborough Hospital; Dr B. Wells, The James Paget Hospital, Great Yarmouth; and Dr Y. F. Williams, The Kent and Canterbury Hospital for donation of patient samples; and to Dr R. Hooper for his help in statistical analysis.
Submitted May 23, 2000; accepted August 9, 2000.
Supported by a grant from the Leukaemia Research Fund, United Kingdom.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Ghulam J. Mufti, The Department of Haematological Medicine, Guy's, King's, Thomas' School of Medicine, Denmark Hill Campus, Bessemer Road, London, SE5 8RX, UK; e-mail: ghulam.mufti{at}kcl.ac.uk.
1. Mufti GJ, Galton DA. Myelodysplastic syndromes: natural history and features of prognostic importance. Clin Haematol. 1986;15:953-971[Medline] [Order article via Infotrieve]. 2. Yoshida Y. Hypothesis: apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome. Leukemia. 1993;7:144-146[Medline] [Order article via Infotrieve].
3.
Raza A, Gezer S, Mundle S, et al.
Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes.
Blood.
1995;86:268-276
4.
Yang E, Korsmeyer SJ.
Molecular thanatopsis: a discourse on the BCL2 family and cell death.
Blood.
1996;88:386-401
5.
Tsujimoto Y, Cossman J, Jaffe E, Croce CM.
Involvement of the bcl-2 gene in human follicular lymphoma.
Science.
1985;228:1440
6.
Delia D, Aiello A, Soligo D, et al.
bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells.
Blood.
1992;79:1291-1298 7. Aguilar-Santelises M, Rottenberg ME, Lewin N, Mellstedt H, Jondal M. Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. Int J Cancer. 1996;69:114-119[Medline] [Order article via Infotrieve].
8.
Campos L, Rouault JP, Sabido O, et al.
High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy.
Blood.
1993;81:3091-3096
9.
Rajapaksa R, Ginzton N, Rott LS, Greenberg PL.
Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells.
Blood.
1996;88:4275-4287 10. Bincoletto C, Saad ST, Soares da Silva E, Queiroz ML. Autonomous proliferation and bcl-2 expression involving haematopoietic cells in patients with myelodysplastic syndrome. Br J Cancer. 1998;78:621-624[Medline] [Order article via Infotrieve].
11.
Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van-Oers MH.
Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis.
Blood.
1994;84:1415-1420 12. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983;31:13-20[Medline] [Order article via Infotrieve]. 13. Parker JE, Fishlock KL, Czepulkowski B, Mijovic A, Pagliuca A, Mufti GJ. `Low risk' myelodysplastic syndrome (MDS) is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic Bcl-2 related proteins. Br J Haematol. 1998;103:1075-1082[Medline] [Order article via Infotrieve]. 14. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189-199[Medline] [Order article via Infotrieve].
15.
Greenberg P, Cox C, LeBeau MM, et al.
International scoring system for evaluating prognosis in myelodysplastic syndromes.
Blood.
1997;89:2079-2088 16. Clark DM, Lampert IA. Apoptosis is a common histopathological finding in myelodysplasia: the correlate of ineffective haematopoiesis. Leuk Lymphoma. 1990;2:415-418. 17. Bogdanovic AD, Trpinac DP, Jankovic GM, Bumbasirevic VZ, Obradovic M, Colovic MD. Incidence and role of apoptosis in myelodysplastic syndrome: morphological and ultrastructural assessment. Leukemia. 1997;11:656-659[Medline] [Order article via Infotrieve]. 18. Bouscary D, De Vos J, Guesnu M, et al. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia. 1997;11:839-845[Medline] [Order article via Infotrieve]. 19. Hellstrom-Lindberg E, Kanter-Lewensohn L, Ost A. Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. Leuk Res. 1997;21:415-425[Medline] [Order article via Infotrieve]. 20. Kurotaki H, Tsushima Y, Nagai K, Yagihashi S. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia. Acta Haematol. 2000;102:115-123[Medline] [Order article via Infotrieve]. 21. Raza A, Alvi S, Borok RZ, et al. Excessive proliferation matched by excessive apoptosis in myelodysplastic syndromes: the cause-effect relationship. Leuk Lymphoma. 1997;27:111-118[Medline] [Order article via Infotrieve]. 22. Darzynkiewicz Z, Bedner E, Traganos F, Murakami T. Critical aspects in the analysis of apoptosis and necrosis. Hum Cell. 1998;11:3-12[Medline] [Order article via Infotrieve]. 23. Prchal JT, Throckmorton DW, Caroll AJ, Fuson EW, Gams RA, Prchal JF. A common progenitor for human myeloid and lymphoid cells. Nature. 1978;274:590-591[Medline] [Order article via Infotrieve]. 24. O'Brien IE, Reutelingsperger CP, Holdaway KM. Annexin-V and TUNEL use in monitoring the progression of apoptosis in plants. Cytometry. 1997;29:28-33[Medline] [Order article via Infotrieve].
25.
Martin SJ, Reutelingsperger CP, McGahon AJ, et al.
Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl.
J Exp Med.
1995;182:1545-1556 26. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis: flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labeled Annexin V. J Immunol Methods. 1995;184:39-51[Medline] [Order article via Infotrieve]. 27. Lepelley P, Campergue L, Grardel N, Preudhomme C, Cosson A, Fenaux P. Is apoptosis a massive process in myelodysplastic syndromes? Br J Haematol. 1996;95:368-371[Medline] [Order article via Infotrieve]. 28. Kliche KO, Andreef M. High expression of phosphatidylserine (PS) in MDS, secondary AML (sAML) and normal progenitors: comparison with primary AML (pAML). Blood. 1997;90:202a.
29.
Kitagawa M, Saito I, Kuwata T, et al.
Overexpression of tumor necrosis factor (TNF)- 30. Gersuk GM, Beckham C, Loken MR, et al. A role for tumour necrosis factor-a, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol. 1998;103:176-188[Medline] [Order article via Infotrieve]. 31. Mundle SD, Reza S, Ali A, et al. Correlation of tumor necrosis factor alpha (TNF alpha) with high Caspase 3-like activity in myelodysplastic syndromes. Cancer Lett. 1999;140:201-207[Medline] [Order article via Infotrieve]. 32. List AF, Glinsmann-Gibson B, Spier C, Taetle R. In vitro and in vivo response to cyclosporin-A in myelodysplastic syndromes: identification of a hypocellular subset responsive to immune suppression. Blood. 1992;80:28a.
33.
Molldrem JJ, Jiang YZ, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett AJ.
Hematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor V 34. Karsdorf A, Dresch C, Metral J, Najean Y. Prognostic value of the combined suicide level of granulocyte progenitors and the labeling index of precursors in preleukemic states and oligoblastic leukemias. Leuk Res. 1983;7:279-286[Medline] [Order article via Infotrieve]. 35. Montecucco C, Riccardi A, Traversi E, et al. Flow cytometric DNA content in myelodysplastic syndromes. Cytometry. 1983;4:238-243[Medline] [Order article via Infotrieve]. 36. Peters SW, Clark RE, Hoy TG, Jacobs A. DNA content and cell cycle analysis of bone marrow cells in myelodysplastic syndromes (MDS). Br J Haematol. 1986;62:239-245[Medline] [Order article via Infotrieve].
© 2000 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  A. Tefferi and J. W. Vardiman Myelodysplastic Syndromes N. Engl. J. Med., November 5, 2009; 361(19): 1872 - 1885. [Full Text] [PDF]
|
|
|
|
 |
|
 D. T. Starczynowski, S. Vercauteren, A. Telenius, S. Sung, K. Tohyama, A. Brooks-Wilson, J. J. Spinelli, C. J. Eaves, A. C. Eaves, D. E. Horsman, et al. High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival Blood, October 15, 2008; 112(8): 3412 - 3424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Novotna, R. Neuwirtova, M. Siskova, and Y. Bagryantseva DNA instability in low-risk myelodysplastic syndromes: refractory anemia with or without ring sideroblasts Hum. Mol. Genet., July 15, 2008; 17(14): 2144 - 2149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Steensma The spectrum of molecular aberrations in myelodysplastic syndromes: in the shadow of acute myeloid leukemia Haematologica, June 1, 2007; 92(6): 723 - 727. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Melchert and A. F. List Management of RBC-Transfusion Dependence Hematology, January 1, 2007; 2007(1): 398 - 404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Schiller, J. Slack, J. D. Hainsworth, J. Mason, M. Saleh, D. Rizzieri, D. Douer, and A. F. List Phase II Multicenter Study of Arsenic Trioxide in Patients With Myelodysplastic Syndromes J. Clin. Oncol., June 1, 2006; 24(16): 2456 - 2464. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Vey, A. Bosly, A. Guerci, W. Feremans, H. Dombret, F. Dreyfus, D. Bowen, A. Burnett, M. Dennis, V. Ribrag, et al. Arsenic Trioxide in Patients With Myelodysplastic Syndromes: A Phase II Multicenter Study J. Clin. Oncol., June 1, 2006; 24(16): 2465 - 2471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Meyer, L. Karawajew, M. Schrappe, W.-D. Ludwig, K.-M. Debatin, and K. Stahnke Cytochrome c-related caspase-3 activation determines treatment response and relapse in childhood precursor B-cell ALL Blood, June 1, 2006; 107(11): 4524 - 4531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Braun, G. Carvalho, A. Coquelle, M.-C. Vozenin, P. Lepelley, F. Hirsch, J.-J. Kiladjian, V. Ribrag, P. Fenaux, and G. Kroemer NF-{kappa}B constitutes a potential therapeutic target in high-risk myelodysplastic syndrome Blood, February 1, 2006; 107(3): 1156 - 1165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Stasi, E. Abruzzese, G. Lanzetta, E. Terzoli, and S. Amadori Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes Ann. Onc., December 1, 2005; 16(12): 1921 - 1927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. B. Kerbauy, V. Lesnikov, N. Abbasi, S. Seal, B. Scott, and H. J. Deeg NF-{kappa}B and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs) Blood, December 1, 2005; 106(12): 3917 - 3925. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sternberg, S. Killick, T. Littlewood, C. Hatton, A. Peniket, T. Seidl, S. Soneji, J. Leach, D. Bowen, C. Chapman, et al. Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome Blood, November 1, 2005; 106(9): 2982 - 2991. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Campioni, P. Secchiero, F. Corallini, E. Melloni, S. Capitani, F. Lanza, and G. Zauli Evidence for a Role of TNF-Related Apoptosis-Inducing Ligand (TRAIL) in the Anemia of Myelodysplastic Syndromes Am. J. Pathol., February 1, 2005; 166(2): 557 - 563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Milojkovic, S. Devereux, N. B. Westwood, G. J. Mufti, N. S. B. Thomas, and A. G. S. Buggins Antiapoptotic Microenvironment of Acute Myeloid Leukemia J. Immunol., December 1, 2004; 173(11): 6745 - 6752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Suarez, M.-B. Vidriales, J. Garcia-Larana, G. Sanz, M.-J. Moreno, A. Lopez, S. Barrena, R. Martinez, M. Tormo, L. Palomera, et al. CD34+ Cells from Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Normal Bone Marrow Display Different Apoptosis and Drug Resistance-Associated Phenotypes Clin. Cancer Res., November 15, 2004; 10(22): 7599 - 7606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Stasi, M. Brunetti, E. Terzoli, E. Abruzzese, and S. Amadori Once-weekly dosing of recombinant human erythropoietin alpha in patients with myelodysplastic syndromes unresponsive to conventional dosing Ann. Onc., November 1, 2004; 15(11): 1684 - 1690. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Brakensiek, F. Langer, H. Kreipe, U. Lehmann, M. T. Voso, A. Scardocci, L. Valentini, F. Guidi, S. Hohaus, and G. Leone Low level of DAP-kinase DNA methylation in myelodysplastic syndrome Blood, September 1, 2004; 104(5): 1586 - 1588. [Full Text] [PDF]
|
|
|
|
|
|
M. T. Voso, A. Scardocci, F. Guidi, G. Zini, A. Di Mario, L. Pagano, S. Hohaus, and G. Leone Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes Blood, January 15, 2004; 103(2): 698 - 700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Del Poeta, A. Venditti, M. I. Del Principe, L. Maurillo, F. Buccisano, A. Tamburini, M. C. Cox, A. Franchi, A. Bruno, C. Mazzone, et al. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML) Blood, March 15, 2003; 101(6): 2125 - 2131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-K. Hofmann, S. de Vos, M. Komor, D. Hoelzer, W. Wachsman, and H. P. Koeffler Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow Blood, November 15, 2002; 100(10): 3553 - 3560. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Vardiman, N. L. Harris, and R. D. Brunning The World Health Organization (WHO) classification of the myeloid neoplasms Blood, September 18, 2002; 100(7): 2292 - 2302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Stasi, M. Brunetti, E. Terzoli, and S. Amadori Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes Blood, March 1, 2002; 99(5): 1578 - 1584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-E. Claessens, D. Bouscary, J.-M. Dupont, F. Picard, J. Melle, S. Gisselbrecht, C. Lacombe, F. Dreyfus, P. Mayeux, and M. Fontenay-Roupie In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis Blood, March 1, 2002; 99(5): 1594 - 1601. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Giles, A. Keating, A. H. Goldstone, I. Avivi, C. L. Willman, and H. M. Kantarjian Acute Myeloid Leukemia Hematology, January 1, 2002; 2002(1): 73 - 110. [Abstract] [Full Text]
|
|
|
|
|
|
P. L. Greenberg, N. S. Young, and N. Gattermann Myelodysplastic Syndromes Hematology, January 1, 2002; 2002(1): 136 - 161. [Abstract] [Full Text]
|
|
|
|
 |
|
 P Greenberg Treatment of myelodysplastic syndrome with agents interfering with inhibitory cytokines Ann Rheum Dis, November 1, 2001; 60(90003): iii41 - 42. [Full Text] [PDF]
|
|
|
|
|
|
L. Teofili, M. Martini, A. Di Mario, S. Rutella, R. Urbano, M. Luongo, G. Leone, and L. M. Larocca Expression of p15ink4b gene during megakaryocytic differentiation of normal and myelodysplastic hematopoietic progenitors Blood, July 15, 2001; 98(2): 495 - 497. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2000 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
2 cytogenetic abnormalities, excluding isolated 5q or 20q deletions
and chromosome 7 abnormalities) and poor risk (> 2 abnormalities
and/or abnormalities of chromosome 7). Apoptosis was additionally
evaluated in patients harboring aberrations of chromosome 7.
protein or messenger
RNA levels
by bone marrow cells from patients with myelodysplastic syndromes.
Leukemia.
1997;11:2049-2054
profiles.
Br J Haematol.
1998;102:1314-1322